# US 2003/0073095 A1 · Homologous 28-kilodalton immunodominant protein genes of Ehrlichia canis and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0073095 A1
- Document ID: US20030073095A1
- Status: Published application
- Kind: A1
- Application number: 10/062,051
- Filed: 2002-01-31
- Published: 2003-04-17
- Earliest claimed: 1998-11-30
- Inventors: David H. Walker; Xue-Jie Yu; Jere W. McBride
- Web page: https://patentgrep.com/patent/US20030073095A1

## CPC

- C07K 14/29: from Richettsiales (O)
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/52: {Bacterial cells; Fungal cells; Protozoal cells}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention is directed to the cloning, sequencing and expression of homologous immunoreactive 28-kDa protein genes, p28-1, -2, -3, -5; -6, -7, -9, from a polymorphic multiple gene family of Ehrlichia canis. Further disclosed is a multigene locus encoding all nine homologous 28-kDa protein genes of Ehrlichia canis. Recombinant Ehrlichia canis 28-kDa proteins react with convalescent phase antiserum from an E. canis-infected dog, and may be useful in the development of vaccines and serodiagnostics that are particularly effective for disease prevention and serodiagnosis.

## Claims

### Claim 1

An isolated DNA sequence encoding a 30-kilodalton protein of Ehrlichia canis, wherein said protein is immunoreactive with anti-Ehrlichia canis serum.

### Claim 2 (depends on 1)

The DNA sequence of claim 1, wherein said protein comprises of an amino acid sequence selected from the group consisting of SEQ ID No. 2, 4, 6, 40, 42, 44 and 46.

### Claim 3 (depends on 2)

The DNA sequence of claim 2, wherein said protein has an N-terminal signal sequence.

### Claim 4 (depends on 3)

The DNA sequence of claim 3, wherein said protein is post-translationally modified to a 28-kilodalton protein.

### Claim 5 (depends on 1)

The DNA sequence of claim 1, wherein said DNA comprises a sequence selected from the group consisting of SEQ ID No. 1, 3, 5, 39, 41, 43 and 45.

### Claim 6 (depends on 1)

The DNA sequence of claim 1, wherein said DNA is contained in a single locus of Ehrlichia canis.

### Claim 7 (depends on 6)

The DNA sequence of claim 6, wherein said locus is a multigene locus of 10,677 base pairs in length.

### Claim 8 (depends on 7)

The DNA sequence of claim 7, wherein said locus contains genes encoding homologous 28-kilodalton proteins of Ehrlichia canis.

### Claim 9 (depends on 8)

The DNA sequence of claim 8, wherein said homologous 28-kilodalton proteins of Ehrlichia canis are selected from the group consisting of p28-1, p28-2, p28-3, p28-4, p28-5, p28-6, p28-7, p28-8 and p28-9.

### Claim 10 (depends on 1)

A vector comprising the DNA sequence of claim 1.

### Claim 11 (depends on 10)

The vector of claim 10, wherein said vector is an expression vector capable of expressing a peptide or polypeptide encoded by a sequence selected from the group consisting of SEQ ID No. 1, 3, 5, 39, 41, 43 and 45 when said expression vector is introduced into a cell.

### Claim 12

A recombinant protein comprises of an amino acid sequence selected from the group consisting of SEQ ID No. 2, 4, 6, 40, 42, 44 and 46.

### Claim 13 (depends on 12)

The recombinant protein of claim 12, wherein said amino acid sequence is encoded by a nucleic acid segment comprising a sequence selected from the group consisting of SEQ ID No. 1, 3, 5, 39, 41, 43 and 45.

### Claim 14

A host cell comprising a nucleic acid segment selected from the group consisting of SEQ ID No. 1, 3, 5, 39, 41, 43 and 45.

### Claim 15 (depends on 12)

A method of producing the recombinant protein of claim 12, comprising the steps of:
obtaining a vector that comprises an expression region comprising a sequence encoding the amino acid sequence selected from the group consisting of SEQ ID No. 2, 4, 6, 40, 42, 44 and 46 operatively linked to a promoter;
transfecting said vector into a cell; and
culturing said cell under conditions effective for expression of said expression region.

### Claim 16

An antibody immunoreactive with a polypeptide comprises of an amino acid sequence selected from the group consisting of SEQ ID No. 2, 4, 6, 40, 42, 44 and 46.

### Claim 17

A method of inhibiting Ehrlichia canis infection in a subject comprising the steps of:
identifying a subject prior to exposure or suspected of being exposed to or infected with Ehrlichia canis; and
administering a composition comprising a 28-kDa antigen of Ehrlichia canis in an amount effective to inhibit Ehrlichia canis infection.

### Claim 18 (depends on 17)

The method of claim 17, wherein said 28-kDa antigen is a recombinant protein comprising an amino acid sequence selected from the group consisting of SEQ ID No. 2, 4, 6, 40, 42, 44 and 46.

### Claim 19 (depends on 18)

The method of claim 18, wherein said recombinant protein is encoded by a gene comprising a sequence selected from the group consisting of SEQ ID No. 1, 3, 5, 39, 41, 43 and 45.

### Claim 20 (depends on 17)

The method of claim 17, wherein said composition comprising a 28-kDa antigen is dispersed in a pharmaceutically acceptable carrier.
